SQZ Biotechnologies (NYSE:SQZ – Get Free Report) and Inhibikase Therapeutics (NYSE:IKT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Earnings and Valuation
This table compares SQZ Biotechnologies and Inhibikase Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SQZ Biotechnologies | $18.16 million | 0.04 | -$79.46 million | ($2.61) | -0.01 |
| Inhibikase Therapeutics | N/A | N/A | -$19.03 million | ($0.39) | -4.10 |
Volatility & Risk
SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and target prices for SQZ Biotechnologies and Inhibikase Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SQZ Biotechnologies | 0 | 0 | 0 | 0 | 0.00 |
| Inhibikase Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Inhibikase Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 275.00%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than SQZ Biotechnologies.
Profitability
This table compares SQZ Biotechnologies and Inhibikase Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
| Inhibikase Therapeutics | N/A | -350.63% | -201.82% |
Institutional and Insider Ownership
38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
SQZ Biotechnologies beats Inhibikase Therapeutics on 7 of the 13 factors compared between the two stocks.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
